Pittsburgh, PA --The twin-island Caribbean Republic of Trinidad and Tobago has the unfortunate distinction of having the highest reported incidence of prostate cancer in the world. The population of the islands is largely of African (40%) or East Indian (40%) descent. A number of studies are underway to study genetic and environmental factors which may contribute to the very high prostate cancer risk among this population. A prostate cancer screening study has been ongoing on the island of Tobago since 1997. About 60% of all Tobago men aged 40-79 are participating in the study, with 3082 men having been screened to date.
Prinicipal investigator, Dr. Clareann H. Bunker Ph.D., Associate Professor, Department of Epidemiology at the Graduate School of Public Health, University of Pittsburgh, together with Dr. Alan Patrick, her co-principal investigator from Tobago, have begun a randomized pilot trial that will test the effectiveness of a tomato lycopene complex in reducing the risk of prostate cancer in Tobago men with biopsy-detected lesions which may have a high risk of progressing to prostate cancer. Dr. Bunker stated “Our underlying promise to the men of Tobago and their families, is to find a way to prevent or slow the progression of prostate cancer”.
Healthy Origins, a Pittsburgh-based manufacturer of specialty supplements, will be supplying study subjects with LYC-O-MATO® - a tomato extract providing 15 mg of lycopene. LYC-O-MATO® is manufactured by LycoRed Natural Products Industries, Ltd.